VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 187 filers reported holding VANDA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 1.50 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,412,627 | -34.8% | 326,997 | -0.5% | 1.00% | -29.0% |
Q2 2023 | $2,165,922 | -4.2% | 328,668 | -1.3% | 1.41% | -5.7% |
Q1 2023 | $2,260,140 | -8.7% | 332,863 | -0.6% | 1.49% | -14.2% |
Q4 2022 | $2,475,310 | -25.2% | 334,954 | 0.0% | 1.74% | -31.3% |
Q3 2022 | $3,309,000 | +7.7% | 334,954 | +18.8% | 2.53% | +12.3% |
Q2 2022 | $3,071,000 | -3.7% | 281,890 | 0.0% | 2.26% | +14.5% |
Q1 2022 | $3,190,000 | -14.6% | 281,890 | +18.4% | 1.97% | -16.1% |
Q4 2021 | $3,735,000 | +178.9% | 238,060 | +204.6% | 2.35% | +152.3% |
Q3 2021 | $1,339,000 | -75.7% | 78,154 | -69.5% | 0.93% | -68.1% |
Q2 2021 | $5,519,000 | +43.2% | 256,546 | 0.0% | 2.92% | +33.0% |
Q1 2021 | $3,853,000 | +12.0% | 256,546 | -2.0% | 2.19% | -0.5% |
Q4 2020 | $3,441,000 | +36.1% | 261,891 | 0.0% | 2.21% | +41.1% |
Q3 2020 | $2,529,000 | +15.7% | 261,891 | +37.1% | 1.56% | +2.4% |
Q2 2020 | $2,185,000 | +100.5% | 190,990 | +81.5% | 1.53% | +49.6% |
Q1 2020 | $1,090,000 | – | 105,234 | – | 1.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARMISTICE CAPITAL, LLC | 1,532,000 | $27,423,000 | 3.23% |
Stonepine Capital Management, LLC | 300,000 | $5,370,000 | 3.16% |
Palo Alto Investors LP | 4,155,670 | $74,386,000 | 3.13% |
GREAT POINT PARTNERS LLC | 497,531 | $8,906,000 | 1.73% |
Avoro Capital Advisors LLC | 988,270 | $17,690,000 | 1.37% |
UNIVERSITY OF NOTRE DAME DU LAC | 157,781 | $2,824,000 | 0.79% |
Birchview Capital, LP | 68,000 | $1,217,000 | 0.63% |
Cheyne Capital Management (UK) LLP | 74,000 | $1,323,000 | 0.48% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 352,604 | $6,311,000 | 0.43% |
361 CAPITAL LLC | 119,554 | $2,140,000 | 0.41% |